Besides type of systemic treatment, the definition of the subgroups was based on current clinically used biological characteristics for tumor subtyping and treatment decisions: patient’s age, tumor histological grade, ER, PR, and HER2 status ( [31]; Supplementary table S2). This evidence concerns the gene ERBB2 and neoplasm.